Wesana Health Holdings Inc. (WSNAF)
USD 0.04
(135.29%)
USD 0.04
(135.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.12 Million USD | -63.29% |
| 2022 | 3.06 Million USD | -77.6% |
| 2021 | 13.68 Million USD | 13959.36% |
| 2020 | 97.3 Thousand USD | -4.97% |
| 2019 | 102.39 Thousand USD | 154.79% |
| 2018 | 40.18 Thousand USD | 0.0% |
| 2015 | 66.91 Thousand USD | -61.03% |
| 2014 | 171.69 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 103.94 Thousand USD | -37.5% |
| 2024 Q2 | 157.2 Thousand USD | 51.27% |
| 2023 FY | 1.12 Million USD | -63.29% |
| 2023 Q4 | 166.3 Thousand USD | -10.53% |
| 2023 Q1 | 445.81 Thousand USD | -30.62% |
| 2023 Q2 | 375.77 Thousand USD | -15.71% |
| 2023 Q3 | 185.87 Thousand USD | -50.53% |
| 2022 FY | 3.06 Million USD | -77.6% |
| 2022 Q4 | 642.58 Thousand USD | 222.16% |
| 2022 Q3 | -526.03 Thousand USD | -118.77% |
| 2022 Q2 | 2.8 Million USD | -40.34% |
| 2022 Q1 | 4.69 Million USD | -14.67% |
| 2021 Q3 | 4.09 Million USD | 54.47% |
| 2021 FY | 13.68 Million USD | 13959.36% |
| 2021 Q4 | 5.5 Million USD | 34.31% |
| 2021 Q1 | 1.42 Million USD | 2502.32% |
| 2021 Q2 | 2.65 Million USD | 85.9% |
| 2020 Q1 | 468.00 USD | 0.0% |
| 2020 Q4 | 54.83 Thousand USD | 58.46% |
| 2020 Q3 | 34.6 Thousand USD | 367.5% |
| 2020 Q2 | 7402.00 USD | 1481.62% |
| 2020 FY | 97.3 Thousand USD | -4.97% |
| 2019 FY | 102.39 Thousand USD | 154.79% |
| 2018 FY | 40.18 Thousand USD | 0.0% |
| 2015 FY | 66.91 Thousand USD | -61.03% |
| 2014 FY | 171.69 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 15.764% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 77.689% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.194% |
| Nascent Biotech, Inc. | 2.22 Million USD | 49.553% |
| Rebus Holdings, Inc. | 664 Thousand USD | -69.414% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.981% |
| Qrons Inc. | 643.67 Thousand USD | -74.763% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -188.76% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.042% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -170.75% |
| Skye Bioscience, Inc. | 13.54 Million USD | 91.697% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.704% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 77.126% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -329.804% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.686% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 61.426% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 25.101% |
| Mesoblast Limited | 5.9 Million USD | 80.94% |
| Marizyme, Inc. | 19.23 Million USD | 94.153% |
| Genus plc | 147.7 Million USD | 99.238% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 87.187% |
| Pharming Group N.V. | 225.49 Million USD | 99.501% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 45.092% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 16.148% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 86.51% |
| ContraFect Corporation | 56.88 Million USD | 98.023% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 74.484% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 23.928% |
| IMV Inc. | 37.7 Million USD | 97.017% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 59.686% |
| MultiCell Technologies, Inc. | 567.42 USD | -198149.974% |
| ONE Bio Corp. | 6.44 Million USD | 82.543% |
| Accustem Sciences Inc. | 3.74 Million USD | 69.974% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.691% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -111.464% |
| Q BioMed Inc. | 3.43 Million USD | 67.267% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.448% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 57.187% |
| Biomind Labs Inc. | 994.18 Thousand USD | -13.149% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.868% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 36.073% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 83.255% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 39.663% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4599.64% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 92.974% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 38.7% |
| GB Sciences, Inc. | 1.42 Million USD | 20.809% |
| Alpha Cognition Inc. | 9.7 Million USD | 88.41% |
| HST Global, Inc. | 140.9 Thousand USD | -698.335% |
| CSL Limited | 3.44 Billion USD | 99.967% |
| Halberd Corporation | 74.84 Thousand USD | -1403.046% |
| Enzolytics Inc. | 2.17 Million USD | 48.387% |
| Agentix Corp. | 1.37 Million USD | 17.995% |
| Resverlogix Corp. | 12.71 Million USD | 91.151% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 69.187% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.927% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -7.75% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 53.225% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 28.774% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 66.963% |
| AVAX Technologies, Inc. | 7.31 Million USD | 84.612% |
| Zenith Capital Corp. | 8.94 Million USD | 87.421% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.864% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -6357.207% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 54.185% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -555.89% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 41.439% |
| Kadimastem Ltd | 2.41 Million USD | 53.325% |
| Helix BioMedix, Inc. | 1.97 Million USD | 42.957% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 89.648% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.104% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -519.836% |
| LadRx Corporation | 3.81 Million USD | 70.489% |
| Cell Source, Inc. | 4.32 Million USD | 73.993% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -21.808% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -21.808% |
| NovAccess Global Inc. | 2.46 Million USD | 54.397% |
| Affymax, Inc. | 39.38 Million USD | 97.144% |
| Itoco Inc. | 919.14 Thousand USD | -22.387% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 73.459% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -0.528% |
| Mobile Lads Corp. | 554.54 Thousand USD | -102.852% |
| CytoDyn Inc. | 18.05 Million USD | 93.771% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4369.427% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -411.142% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 20.769% |
| SYBLEU INC | 160.87 Thousand USD | -599.24% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 38.067% |
| International Stem Cell Corporation | 5.27 Million USD | 78.659% |
| Bioxytran, Inc. | 3.82 Million USD | 70.553% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2036.906% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5429.715% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.898% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 30.475% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -52.875% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 63.841% |
| Neutra Corp. | 243.82 Thousand USD | -361.367% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 93.556% |
| PureTech Health plc | 144.59 Million USD | 99.222% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 94.51% |
| IXICO plc | 4.7 Million USD | 76.101% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 87.213% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.045% |
| CSL Limited | 3.89 Billion USD | 99.971% |
| Cellectis S.A. | 97.32 Million USD | 98.844% |